Companies › Adcentrx Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ADRX-0405 Anti-STEAP1 antibody-drug conjugate | STEAP1 | Phase 1 | Solid Tumors | Dec 2026 |
| ADRX-0706 anti-Nectin-4 antibody-drug conjugate | NECTIN4 | Phase 1 | Solid Tumors | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06710379 | ADRX-0405 | Phase 1 | Solid Tumors | Oncology | Dec 2026 |
| NCT06036121 | ADRX-0706 | Phase 1 | Solid Tumors | Oncology | Dec 2026 |
BicycleTx Mabwell (Shanghai) Bioscience Aktis Oncology Tianjin ConjuStar Biologics Regeneron Pharmaceuticals Innate Pharma Astellas Samsung Bioepis Beijing Biotech Akeso
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.